With an aim to strengthen its branded portfolio, Pharma major Lupin, would be launching additional products either from its pipeline or from strategic brand acquisitions that have been developed and filed with the USFDA.
The company's US revenues grew by 54% to Rs 3,683 crore during FY 2013, up from Rs 2,393 crore in FY 2012. Meanwhile, new launches contributed 42% of the US generics revenues.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
